{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:19:14Z","timestamp":1788898754648,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03042-1","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T09:07:23Z","timestamp":1733130443000},"page":"734-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon A.","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7410-9709","authenticated-orcid":false,"given":"Natalie J.","family":"Shiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-1708","authenticated-orcid":false,"given":"Timothy P.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-0845","authenticated-orcid":false,"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"3042_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"3042_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"3042_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5\u201332.","journal-title":"Arthritis Rheumatol"},{"key":"3042_CR4","unstructured":"Tremfya: Package insert. Horsham: Janssen Biotech, Inc.; 2024."},{"key":"3042_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115\u201325.","journal-title":"Lancet"},{"key":"3042_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet"},{"key":"3042_CR7","unstructured":"Taltz: Package insert. Indianapolis: Eli Lilly and Company; 2022."},{"key":"3042_CR8","unstructured":"Cosentyx: Package insert. East Hanover: Novartis; 2023."},{"key":"3042_CR9","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/acr.24782","volume":"74","author":"D Sumpton","year":"2022","unstructured":"Sumpton D, Kelly A, Craig JC, et al. Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment. Arthritis Care Res (Hoboken). 2022;74:1234\u201343.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3042_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7: e001457.","journal-title":"RMD Open"},{"key":"3042_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475\u201385.","journal-title":"Arthritis Rheumatol"},{"key":"3042_CR12","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Ogdie A, Tesser J, et al. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. Rheumatol Ther. 2023;10:1479\u2013501.","journal-title":"Rheumatol Ther"},{"key":"3042_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s40801-024-00428-z","volume":"11","author":"J Walsh","year":"2024","unstructured":"Walsh J, Lin I, Zhao R, et al. Comparison of real-world on-label treatment persistence in patients with psoriatic arthritis receiving guselkumab versus subcutaneous TNF inhibitors. Drugs Real World Outcomes. 2024;11:487\u201399. https:\/\/doi.org\/10.1007\/s40801-024-00428-z.","journal-title":"Drugs Real World Outcomes"},{"key":"3042_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/pds.4950","volume":"29","author":"H Lee","year":"2020","unstructured":"Lee H, Ford JA, Jin Y, et al. Validation of claims-based algorithms for psoriatic arthritis. Pharmacoepidemiol Drug Saf. 2020;29:404\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3042_CR15","first-page":"90","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ferrante SA, Fitzgerald T, Pericone CD, Wu B. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29:90\u2013100.","journal-title":"J Manag Care Spec Pharm"},{"key":"3042_CR16","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/pds.1673","volume":"17","author":"PC Austin","year":"2008","unstructured":"Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17:1202\u201317.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3042_CR17","first-page":"S104","volume":"33","author":"P Mease","year":"2015","unstructured":"Mease P. A short history of biological therapy for psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S104\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"3042_CR18","first-page":"408","volume":"11","author":"Y Xu","year":"2018","unstructured":"Xu Y, Sudharshan L, Hsu MA, et al. Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis. Am Health Drug Benefits. 2018;11:408\u201317.","journal-title":"Am Health Drug Benefits"},{"key":"3042_CR19","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/acr2.11657","volume":"6","author":"PJ Mease","year":"2024","unstructured":"Mease PJ, Ogdie A, Tesser J, et al. Improvements in patient-reported outcomes through six months of guselkumab treatment in patients with active psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. ACR Open Rheumatol. 2024;6:304\u201311.","journal-title":"ACR Open Rheumatol"},{"key":"3042_CR20","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/acr2.11347","volume":"3","author":"MJ Murage","year":"2021","unstructured":"Murage MJ, Princic N, Park J, et al. Real-world treatment patterns and healthcare costs in patients with psoriatic arthritis treated with ixekizumab: a retrospective study. ACR Open Rheumatol. 2021;3:879\u201387.","journal-title":"ACR Open Rheumatol"},{"key":"3042_CR21","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2217\/cer-2019-0023","volume":"8","author":"KR Oelke","year":"2019","unstructured":"Oelke KR, Chambenoit O, Majjhoo AQ, Gray S, Higgins K, Hur P. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019;8:607\u201321.","journal-title":"J Comp Eff Res"},{"key":"3042_CR22","first-page":"24","volume":"29","author":"LN Pizzicato","year":"2023","unstructured":"Pizzicato LN, Vadhariya A, Birt J, et al. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States. J Manag Care Spec Pharm. 2023;29:24\u201335.","journal-title":"J Manag Care Spec Pharm"},{"key":"3042_CR23","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1080\/09546634.2021.1950600","volume":"33","author":"C Xu","year":"2022","unstructured":"Xu C, Teeple A, Wu B, Fitzgerald T, Feldman SR. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a US commercially insured population. J Dermatol Treat. 2022;33:2270\u20137.","journal-title":"J Dermatol Treat"},{"key":"3042_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13317-013-0057-4","volume":"5","author":"B Marinoni","year":"2014","unstructured":"Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5:9\u201319.","journal-title":"Auto Immun Highlights"},{"issue":"Suppl 1","key":"3042_CR25","first-page":"S12","volume":"20","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskelet Care. 2022;20(Suppl 1):S12\u201321.","journal-title":"Musculoskelet Care"},{"key":"3042_CR26","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1084\/jem.20060244","volume":"203","author":"JR Chan","year":"2006","unstructured":"Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577\u201387.","journal-title":"J Exp Med"},{"key":"3042_CR27","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1186\/ar3817","volume":"14","author":"R Celis","year":"2012","unstructured":"Celis R, Planell N, Fern\u00e1ndez-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther. 2012;14:R93.","journal-title":"Arthritis Res Ther"},{"key":"3042_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/annrheumdis-2023-eular.826","volume":"82","author":"D McGonagle","year":"2023","unstructured":"McGonagle D, Atreya R, Abreu M, et al. Guselkumab, an IL-23p19 subunit\u2013specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells. Ann Rheum Dis. 2023;82:1128\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3042_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2024","unstructured":"Strober B, Coates LC, Lebwohl MG, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47:39\u201357.","journal-title":"Drug Saf"},{"key":"3042_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40744-021-00344-6","volume":"8","author":"T Hunter","year":"2021","unstructured":"Hunter T, Nguyen C, Birt J, et al. Pain medication and corticosteroid use in ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis in the United States: a retrospective observational study. Rheumatol Ther. 2021;8:1371\u201382.","journal-title":"Rheumatol Ther"},{"key":"3042_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/bjd.19865","volume":"185","author":"MT Taylor","year":"2021","unstructured":"Taylor MT, Noe MH, Horton DB, Barbieri JS. Trends in opioid prescribing at outpatient visits for psoriasis and psoriatic arthritis. Br J Dermatol. 2021;185:200\u20131.","journal-title":"Br J Dermatol"},{"key":"3042_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s10067-024-06945-0","volume":"43","author":"A Sheahan","year":"2024","unstructured":"Sheahan A, Anjohrin S, Suruki R, Stark JL, Sloan VS. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases. Clin Rheumatol. 2024;43:1897\u2013907.","journal-title":"Clin Rheumatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03042-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03042-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03042-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:52:02Z","timestamp":1738407122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03042-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03042-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip J Mease has received consulting fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Immagene, Janssen, Novartis, Pfizer, UCB, and Ventyx; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; and research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, and UCB. Shannon A Ferrante, Natalie J Shiff, Timothy P Fitzgerald, and Soumya D Chakravarty are or were employees of Janssen Scientific Affairs, LLC, a Johnson & Johnson company at the time this work was performed and own stock in Johnson & Johnson. Natalie J Shiff also owns stock in or has owned stock in AbbVie, Gilead, Iovance, Novo-Nordisk, and Pfizer within the past 3 years and is currently an employee of Alpine Immune Sciences, A Vertex Company. Jessica A Walsh has received consulting fees for AbbVie, Eli Lilly, Janssen, Novartis, and UCB; and research funding from AbbVie, Merck, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The IQVIA PharMetrics\u00ae Plus database, used under license for this study, complies with Health Insurance Portability and Accountability Act (HIPAA) regulations. The data obtained from these analyses were de-identified; thus, no Institutional Review Board approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}